Show simple item record

Resultados de pacientes con linfoma del manto tratados en la Red de Salud UC-Christus: impacto de terapias basadas en citarabina y trasplante hematopoyético

CYTARABINE AND HEMATOPOIETIC CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA. ANALYSIS OF 20 PATIENTS

dc.contributores-ES
dc.contributoren-US
dc.creatorCampbell, James
dc.creatorHurtado, Sebastián
dc.creatorKutz, Consuelo
dc.creatorSoto, Katherine
dc.creatorErnst, Daniel
dc.date2018-12-27
dc.date.accessioned2019-11-11T18:27:25Z
dc.date.available2019-11-11T18:27:25Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/7047
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111127
dc.descriptionBackground: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with Cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with Rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with Rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% % respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with Rituximab or HCT was associated with better PFS (48 vs 21 months, pes-ES
dc.descriptionBackground: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with Cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with Rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with Rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% % respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with Rituximab or HCT was associated with better PFS (48 vs 21 months, pen-US
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/7047/4608
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37085
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37088
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37089
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37090
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37091
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37092
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37093
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37094
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37095
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37096
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37097
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37098
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37099
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37101
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37102
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37103
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37104
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/38006
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/38005
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/38162
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/7047/37296
dc.sourceRevista Médica de Chile; Vol. 147, núm. 1 (2019): ENERO 2019es-ES
dc.source0034-9887
dc.subjectLymphoma, Mantle-Cell; Cytarabine; Hematopoietic Stem Cell Transplantation; Rituximab; Chilees-ES
dc.subjectLymphoma, Mantle-Cell; Cytarabine; Hematopoietic Stem Cell Transplantation; Rituximab; Chileen-US
dc.titleResultados de pacientes con linfoma del manto tratados en la Red de Salud UC-Christus: impacto de terapias basadas en citarabina y trasplante hematopoyéticoes-ES
dc.titleCYTARABINE AND HEMATOPOIETIC CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA. ANALYSIS OF 20 PATIENTSen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record